- Home
- NDRA vs THAR Comparison
NDRA vs THAR Comparison
Compare NDRA & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDRA
- THAR
- Stock Information
- Founded
- NDRA 2007
- THAR 2017
- Country
- NDRA United States
- THAR United States
- Employees
- NDRA N/A
- THAR N/A
- Industry
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- NDRA Health Care
- THAR Health Care
- Exchange
- NDRA Nasdaq
- THAR Nasdaq
- Market Cap
- NDRA 2.1M
- THAR 2.4M
- IPO Year
- NDRA 2017
- THAR 2022
- Fundamental
- Price
- NDRA $3.98
- THAR $1.20
- Analyst Decision
- NDRA Strong Buy
- THAR Strong Buy
- Analyst Count
- NDRA 1
- THAR 1
- Target Price
- NDRA $50.00
- THAR $17.00
- AVG Volume (30 Days)
- NDRA 355.0K
- THAR 97.3K
- Earning Date
- NDRA 05-13-2025
- THAR 05-08-2025
- Dividend Yield
- NDRA N/A
- THAR N/A
- EPS Growth
- NDRA N/A
- THAR N/A
- EPS
- NDRA N/A
- THAR N/A
- Revenue
- NDRA N/A
- THAR N/A
- Revenue This Year
- NDRA N/A
- THAR N/A
- Revenue Next Year
- NDRA N/A
- THAR N/A
- P/E Ratio
- NDRA N/A
- THAR N/A
- Revenue Growth
- NDRA N/A
- THAR N/A
- 52 Week Low
- NDRA $2.97
- THAR $0.95
- 52 Week High
- NDRA $665.00
- THAR $6.45
- Technical
- Relative Strength Index (RSI)
- NDRA 51.65
- THAR 43.85
- Support Level
- NDRA $3.28
- THAR $1.05
- Resistance Level
- NDRA $3.98
- THAR $1.28
- Average True Range (ATR)
- NDRA 0.92
- THAR 0.11
- MACD
- NDRA 0.02
- THAR 0.02
- Stochastic Oscillator
- NDRA 31.76
- THAR 75.58
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.